Professur für Translationale Frauenheilkunde und Geburtshilfe


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Evaluation of ChatGPT’s Potential in Tailoring Gynecological Cancer Therapies (2024) Krückel A, Brückner L, Psilopatis I, Fasching P, Beckmann M, Emons J Journal article Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study (2024) Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, et al. Journal article Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2024 (2024) Thill M, Janni W, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, et al. Journal article, Review article Discussion of ABC7 Consensus and German Recommendations (2024) Untch M, Ditsch N, Fasching P, Busch S, Ettl J, Haidinger R, Harbeck N, et al. Journal article, Review article Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry (2024) Hartkopf AD, Walter CB, Kolberg HC, Hadji P, Tesch H, Fasching P, Ettl J, et al. Journal article CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs (2024) Schneeweiss A, Brucker SY, Hübner H, Volmer LL, Hack C, Seitz K, Rübner M, et al. Journal article, Review article Power-MF: Robust fetal QRS detection from non-invasive fetal electrocardiogram recordings (2024) Jäger K, Nissen M, Rahm S, Titzmann A, Fasching P, Beilner J, Eskofier B, Leutheuser H Journal article PROTAC Drugs in Cancer Care (2024) Fasching P Journal article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis (2024) Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, Barrios C, et al. Journal article